International Trade

With more than one-fifth of the world’s population, China is an important market for biotech products and is increasingly a key global player in biotech research, development and manufacturing.

WASHINGTON, D.C. (Tuesday, April 19, 2011) - The Biotechnology Industry Organization (BIO) announced today that Dr. Jörg Reinhardt, CEO of Bayer HealthCare, will provide the keynote address at the BIO China International Conference to be held October 12-13 in Shanghai, China. The event will bring together biotechnology and pharmaceutical leaders to explore business opportunities with life science companies in China.

The world’s largest biotech hubs are busy planning their delegations’ visits to the  BIO International Convention  next month. The international program at the Convention will be one of the most robust to date, with International Case Studies, breakout sessions focused on globalization and Super Sessions focused on the emerging markets.

Scientific American will release the third annual Worldview: A Global Biotechnology Perspective at this year’s BIO International Convention.

Three biotech luminaries who have succeeded against all odds share their experiences building a biotech company from the ground up in Brazil, China and India.

Fifteen years after Dolly, the first mammal to be cloned from an adult cell rather than an embryo, made headlines, the process of livestock cloning is increasingly gaining acceptance as a viable means of satisfying demand for sustainable food production.

Patent systems can provide an advantage to society by rewarding the development of new inventions, promoting the advancement of technology and protecting the investor.  Patents often are the most important, and sometimes only, asset of a biotech company. Patents and related rights must be obtained in a timely and predictable manner and the ability to enforce those patents is critical.

Upward trends and investment opportunities will be focus of BIO’s World Congress in May.

Overhauled BIOTradeStatus lets users search for the latest information on hundreds of products.

ISAAA data shows countries around the world have embraced agricultural biotechnology.

Bringing biotechs into global health R&D.

This month, BIO is leading a delegation of biopharma CEOs to China for meetings with members of the Chinese biotech community and government leaders. The mission illustrates a strong commitment on behalf of the western biotechnology industry to encourage China to strengthen its support for biotech innovation and take steps to enhance greater investment and collaboration with companies in China. The series of meetings between China’s local industry and government leaders and biotech CEOs will lay the foundation for increased cooperation to help biotech flourish in China.

Scientific American will release the third annual Worldview: A Global Biotechnology Perspective at this year’s BIO International Convention.  Created in partnership with BIO, the publication explores the diverse economic regions of the world, highlighting success stories, policy achievements, cutting-edge science and the unique challenges that lie ahead. This year’s report focuses on BRIC (Brazil, Russia, India and China) country efforts to build local biotechnology hubs. 

Brenda Herschbach Jarrell and Jennifer Groves present an overview of the IP landscape in China, India, Brazil and Korea.

July 10 2013
Therapeutic biologics are an opportunity to address unmet patient needs, drive innovation, and assist China's transformation into a knowledge-intensive economy.
June 19 2013
The TTIP represents a profoundly important opportunity to advance progress in these areas. The following comments represent BIO’s initial suggestions for the formulation of negotiating objectives relevant to biotechnology.  
June 3 2013
BIO appreciates the opportunity to respond to the Request for Comments issued by the U.S. Trade Representative on objectives to be pursued in the negotiation of a Transatlantic Trade and Investment Partnership (TTIP) agreement. 
February 8 2013
Biotechnology companies provide unique benefits to the United States and the world. In the health care sector alone, the industry has developed and commercialized more than 300 biotechnology drugs and diagnostics and there are over 400 products in the pipeline.
January 18 2013
The Biotechnology Industry Organization (BIO) appreciates the opportunity to provide comments in response to the Controller General of Patents Designs and Trademarks in India on the "Draft Guidelines for Examination of Biotechnology Applications" hereafter referred to as "Draft Guidelines", or "Guidelines".
June 20 2012
The Biotechnology Industry Organization(BIO) unveiled a report on the role of intellectual property rights in encouraging upstream research and development as well as downstream commercialization of biotechnology at the 2012 BIO International Convention.
June 6 2012
The report will be released at a Super Session, titled "International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard."
February 21 2011
The Biotechnology Industry Organization (BIO) stresses the critical importance of protecting intellectual property abroad in comments recently filed with the U.S. Trade Representative (USTR) on the 2011 Special 301 Review.
April 6 2010
The Obama Administration has made substantial progress to avoid retaliatory measures in a long-running “cotton dispute” brought by Brazil against the United States.
March 2 2010
The Biotechnology Industry Organization (BIO) applauded today’s announcement by the European Commission to authorize the cultivation of a biotech potato, as well as the commercialization of three varieties of biotech maize for food and feed uses and import and processing.